Literature DB >> 25335457

IL-6 blockade in chronic inflammatory diseases.

Antonia Puchner1, Stephan Blüml.   

Abstract

Proinflammatory cytokines are centrally involved in the pathogenesis of various rheumatic diseases. Interleukin (IL)-6 is a prototypic representative of this family. Basic research has uncovered a multitude of functions for this cytokine, such as immune regulation, hematopoiesis, inflammation, and oncogenesis (Fig. 1). In recent years, agents blocking the actions of IL-6 have been developed for the therapy of rheumatologic inflammatory diseases. While in some diseases, most notably rheumatoid arthritis, the clinical efficacy of these drugs was excellent, the results of clinical trials in other chronic inflammatory diseases were heterogeneous. In this review, we will summarize the data currently available on IL-6 blockade in chronic inflammatory diseases and will also discuss the safety issues of blocking this cytokine.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25335457     DOI： 10.1007/s10354-014-0321-x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  47 in total

1.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

2.  Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab.

Authors:  Atsushi Ogata; Noriko Umegaki; Ichiro Katayama; Atsushi Kumanogoh; Toshio Tanaka
Journal:  Joint Bone Spine       Date:  2011-10-01       Impact factor: 4.929

3.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

4.  Interleukin 6 blockade: tocilizumab in psoriatic arthritis.

Authors:  Fabiola Atzeni; Donatella Ventura; Alberto Batticciotto; Laura Boccassini; Piercarlo Sarzi-Puttini
Journal:  J Rheumatol Suppl       Date:  2012-07

5.  Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.

Authors:  S Unizony; L Arias-Urdaneta; E Miloslavsky; S Arvikar; A Khosroshahi; B Keroack; J R Stone; J H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-11       Impact factor: 4.794

6.  Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.

Authors:  N E Roche; J W Fulbright; A D Wagner; G G Hunder; J J Goronzy; C M Weyand
Journal:  Arthritis Rheum       Date:  1993-09

7.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Authors:  Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Mod Rheumatol       Date:  2008-11-01       Impact factor: 3.023

8.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors:  N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103

9.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.

Authors:  Iain B McInnes; Joachim Sieper; Jürgen Braun; Paul Emery; Désirée van der Heijde; John D Isaacs; Georg Dahmen; Jürgen Wollenhaupt; Hendrik Schulze-Koops; Joseph Kogan; Shenglin Ma; Martin M Schumacher; Arthur P Bertolino; Wolfgang Hueber; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2013-01-29       Impact factor: 19.103

10.  Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Authors:  Tom W J Huizinga; Roy M Fleischmann; Martine Jasson; Allen R Radin; Janet van Adelsberg; Stefano Fiore; Xiaohong Huang; George D Yancopoulos; Neil Stahl; Mark C Genovese
Journal:  Ann Rheum Dis       Date:  2013-12-02       Impact factor: 19.103
View more
  6 in total

1.  Markers or Makers: Inflammatory Cytokines in Treatment-Resistant Hypertension

Authors:  Natalia R Barbaro; David G Harrison
Journal:  Hypertension       Date:  2019-04       Impact factor: 10.190

Review 2.  [Biologicals and small molecules for rheumatoid arthritis].

Authors:  Stephan Blüml
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

Review 3.  Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability.

Authors:  Etheresia Pretorius; Oore-Ofe Akeredolu; Prashilla Soma; Douglas B Kell
Journal:  Exp Biol Med (Maywood)       Date:  2016-11-26

4.  Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles.

Authors:  Philipp Arnold; Wiebke Lückstädt; Wenjia Li; Inga Boll; Juliane Lokau; Christoph Garbers; Ralph Lucius; Stefan Rose-John; Christoph Becker-Pauly
Journal:  Cells       Date:  2020-05-24       Impact factor: 6.600

5.  Development and Validation of a Reporter-Cell-Line-Based Bioassay for Therapeutic Soluble gp130-Fc.

Authors:  Lei Yu; Chuncui Jia; Wenrong Yao; Dening Pei; Xi Qin; Chunming Rao; Junzhi Wang
Journal:  Molecules       Date:  2019-10-25       Impact factor: 4.411

6.  Serum Antioxidant Parameters are Significantly Increased in Patients with Type 2 Diabetes Mellitus after Consumption of Chinese Propolis: A Randomized Controlled Trial Based on Fasting Serum Glucose Level.

Authors:  Weina Gao; Lingling Pu; Jingyu Wei; Zhanxin Yao; Yawen Wang; Tala Shi; Liting Zhao; Changya Jiao; Changjiang Guo
Journal:  Diabetes Ther       Date:  2017-12-06       Impact factor: 2.945
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.